Hims & Hers Health Inc (HIMS) Stock Price Today — Live Chart and Analysis

HIMS moves primarily on FDA regulatory news affecting its GLP-1 compounding business, quarterly subscriber and revenue growth figures, and broader telehealth sector sentiment. Positive earnings beats or new category launches tend to lift the stock, regulatory restrictions on compounded weight-loss drugs historically cause sharp drops.

The main drivers are FDA policy on compounded GLP-1 medications, subscriber growth and retention, revenue per user trends, competitive pressure from branded weight-loss drug makers (Novo Nordisk, Eli Lilly), new health category launches, and international expansion progress.

HIMS has grown revenue from $527M in 2022 to $2.35B in 2025 and turned consistently profitable. However, a significant portion of recent growth relied on compounded semaglutide — a category now under active FDA regulatory pressure. Investors need to weigh strong subscriber momentum against GLP-1 regulatory risk and execution on category diversification. This is not financial advice.

Create an account on IQ Option and you can start trading immediately on a free demo account with $10,000 - no verification required. To trade with real money, deposit from $10, find HIMS in the stocks section, select your position size, and choose to buy or sell based on your view of the stock's direction.